[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease
We investigated the applicability [123I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD. Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [1...
Gespeichert in:
| Veröffentlicht in: | Journal of Neural Transmission 2001-01, Vol.108 (8-9), p.1011-1019 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1019 |
|---|---|
| container_issue | 8-9 |
| container_start_page | 1011 |
| container_title | Journal of Neural Transmission |
| container_volume | 108 |
| creator | WINOGRODZKA, A BERGMANS, P BOOIJ, J VAN ROYEN, E. A JANSSEN, A. G. M WOLTERS, E. Ch |
| description | We investigated the applicability [123I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD. Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [123I]FP-CIT binding to the striatum was used as the outcome measure. The mean annual decrease in striatal [123I]FP-CIT binding ratios was found to be about 8% (of the baseline mean). In order to demonstrate a significant effect (p < 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies. |
| doi_str_mv | 10.1007/s007020170019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72287718</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72287718</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-cfc8a3978df80a911f207eae64ae01404bc64ccb542982a41f9d0d85a7e617083</originalsourceid><addsrcrecordid>eNqF0TGP1DAQBWALgbi9g5IWuUB3VcCOHdsp0eoOVjqJlVgqhKJZZ7xnSOLF4xT77wm6lYCKZmaKT6-Yx9grKd5KIew7WoaohbRCyPYJW0mtmkpqo56ylVBCVG1j9AW7JPouFiKte84uliWNVGbFTl9lrTbf7rbVerPjn7e36x2PxIHPhGEe-IjlIfW8JD6mKZaUeXlAnqEgT4H36QhjnDAfouc9HnA5ocQ08ThxhDycKipwQL6F_CNOlKYb4n0kBMIX7FmAgfDleV-xL3e3u_XH6v7Th836_X3ldaNL5YN3oFrr-uAEtFKGWlgENBpQSC303hvt_b7Rdetq0DK0vehdAxbN8hSnrtj1Y-4xp58zUunGSB6HASZMM3W2rp218v9QOmmVcWaB1SP0ORFlDN0xxxHyqZOi-11K908pi399Dp73I_Z_9LmFBbw5AyAPQ8gw-Uh_pbaNqhv1C3sKkow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18173686</pqid></control><display><type>article</type><title>[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease</title><source>MEDLINE</source><source>SpringerLink</source><creator>WINOGRODZKA, A ; BERGMANS, P ; BOOIJ, J ; VAN ROYEN, E. A ; JANSSEN, A. G. M ; WOLTERS, E. Ch</creator><creatorcontrib>WINOGRODZKA, A ; BERGMANS, P ; BOOIJ, J ; VAN ROYEN, E. A ; JANSSEN, A. G. M ; WOLTERS, E. Ch</creatorcontrib><description>We investigated the applicability [123I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD. Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [123I]FP-CIT binding to the striatum was used as the outcome measure. The mean annual decrease in striatal [123I]FP-CIT binding ratios was found to be about 8% (of the baseline mean). In order to demonstrate a significant effect (p < 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies.</description><identifier>ISSN: 0300-9564</identifier><identifier>EISSN: 1435-1463</identifier><identifier>DOI: 10.1007/s007020170019</identifier><identifier>PMID: 11716136</identifier><identifier>CODEN: JNTMAH</identifier><language>eng</language><publisher>Wien: Springer</publisher><subject>Adult ; Aged ; Binding Sites - drug effects ; Binding Sites - physiology ; Binding, Competitive - drug effects ; Binding, Competitive - physiology ; Biological and medical sciences ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Disease Progression ; Dopamine - metabolism ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Neostriatum - diagnostic imaging ; Neostriatum - pathology ; Neural Pathways - diagnostic imaging ; Neural Pathways - pathology ; Neurology ; Neuroprotective Agents - pharmacology ; Parkinson Disease - diagnostic imaging ; Parkinson Disease - pathology ; Presynaptic Terminals - diagnostic imaging ; Presynaptic Terminals - pathology ; Radionuclide Imaging ; Substantia Nigra - diagnostic imaging ; Substantia Nigra - pathology ; Tropanes - pharmacokinetics</subject><ispartof>Journal of Neural Transmission, 2001-01, Vol.108 (8-9), p.1011-1019</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-cfc8a3978df80a911f207eae64ae01404bc64ccb542982a41f9d0d85a7e617083</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1095325$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11716136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WINOGRODZKA, A</creatorcontrib><creatorcontrib>BERGMANS, P</creatorcontrib><creatorcontrib>BOOIJ, J</creatorcontrib><creatorcontrib>VAN ROYEN, E. A</creatorcontrib><creatorcontrib>JANSSEN, A. G. M</creatorcontrib><creatorcontrib>WOLTERS, E. Ch</creatorcontrib><title>[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease</title><title>Journal of Neural Transmission</title><addtitle>J Neural Transm (Vienna)</addtitle><description>We investigated the applicability [123I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD. Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [123I]FP-CIT binding to the striatum was used as the outcome measure. The mean annual decrease in striatal [123I]FP-CIT binding ratios was found to be about 8% (of the baseline mean). In order to demonstrate a significant effect (p < 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies.</description><subject>Adult</subject><subject>Aged</subject><subject>Binding Sites - drug effects</subject><subject>Binding Sites - physiology</subject><subject>Binding, Competitive - drug effects</subject><subject>Binding, Competitive - physiology</subject><subject>Biological and medical sciences</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Disease Progression</subject><subject>Dopamine - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neostriatum - diagnostic imaging</subject><subject>Neostriatum - pathology</subject><subject>Neural Pathways - diagnostic imaging</subject><subject>Neural Pathways - pathology</subject><subject>Neurology</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Parkinson Disease - diagnostic imaging</subject><subject>Parkinson Disease - pathology</subject><subject>Presynaptic Terminals - diagnostic imaging</subject><subject>Presynaptic Terminals - pathology</subject><subject>Radionuclide Imaging</subject><subject>Substantia Nigra - diagnostic imaging</subject><subject>Substantia Nigra - pathology</subject><subject>Tropanes - pharmacokinetics</subject><issn>0300-9564</issn><issn>1435-1463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0TGP1DAQBWALgbi9g5IWuUB3VcCOHdsp0eoOVjqJlVgqhKJZZ7xnSOLF4xT77wm6lYCKZmaKT6-Yx9grKd5KIew7WoaohbRCyPYJW0mtmkpqo56ylVBCVG1j9AW7JPouFiKte84uliWNVGbFTl9lrTbf7rbVerPjn7e36x2PxIHPhGEe-IjlIfW8JD6mKZaUeXlAnqEgT4H36QhjnDAfouc9HnA5ocQ08ThxhDycKipwQL6F_CNOlKYb4n0kBMIX7FmAgfDleV-xL3e3u_XH6v7Th836_X3ldaNL5YN3oFrr-uAEtFKGWlgENBpQSC303hvt_b7Rdetq0DK0vehdAxbN8hSnrtj1Y-4xp58zUunGSB6HASZMM3W2rp218v9QOmmVcWaB1SP0ORFlDN0xxxHyqZOi-11K908pi399Dp73I_Z_9LmFBbw5AyAPQ8gw-Uh_pbaNqhv1C3sKkow</recordid><startdate>20010101</startdate><enddate>20010101</enddate><creator>WINOGRODZKA, A</creator><creator>BERGMANS, P</creator><creator>BOOIJ, J</creator><creator>VAN ROYEN, E. A</creator><creator>JANSSEN, A. G. M</creator><creator>WOLTERS, E. Ch</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20010101</creationdate><title>[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease</title><author>WINOGRODZKA, A ; BERGMANS, P ; BOOIJ, J ; VAN ROYEN, E. A ; JANSSEN, A. G. M ; WOLTERS, E. Ch</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-cfc8a3978df80a911f207eae64ae01404bc64ccb542982a41f9d0d85a7e617083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Binding Sites - drug effects</topic><topic>Binding Sites - physiology</topic><topic>Binding, Competitive - drug effects</topic><topic>Binding, Competitive - physiology</topic><topic>Biological and medical sciences</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Disease Progression</topic><topic>Dopamine - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neostriatum - diagnostic imaging</topic><topic>Neostriatum - pathology</topic><topic>Neural Pathways - diagnostic imaging</topic><topic>Neural Pathways - pathology</topic><topic>Neurology</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Parkinson Disease - diagnostic imaging</topic><topic>Parkinson Disease - pathology</topic><topic>Presynaptic Terminals - diagnostic imaging</topic><topic>Presynaptic Terminals - pathology</topic><topic>Radionuclide Imaging</topic><topic>Substantia Nigra - diagnostic imaging</topic><topic>Substantia Nigra - pathology</topic><topic>Tropanes - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WINOGRODZKA, A</creatorcontrib><creatorcontrib>BERGMANS, P</creatorcontrib><creatorcontrib>BOOIJ, J</creatorcontrib><creatorcontrib>VAN ROYEN, E. A</creatorcontrib><creatorcontrib>JANSSEN, A. G. M</creatorcontrib><creatorcontrib>WOLTERS, E. Ch</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Neural Transmission</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WINOGRODZKA, A</au><au>BERGMANS, P</au><au>BOOIJ, J</au><au>VAN ROYEN, E. A</au><au>JANSSEN, A. G. M</au><au>WOLTERS, E. Ch</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease</atitle><jtitle>Journal of Neural Transmission</jtitle><addtitle>J Neural Transm (Vienna)</addtitle><date>2001-01-01</date><risdate>2001</risdate><volume>108</volume><issue>8-9</issue><spage>1011</spage><epage>1019</epage><pages>1011-1019</pages><issn>0300-9564</issn><eissn>1435-1463</eissn><coden>JNTMAH</coden><abstract>We investigated the applicability [123I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD. Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [123I]FP-CIT binding to the striatum was used as the outcome measure. The mean annual decrease in striatal [123I]FP-CIT binding ratios was found to be about 8% (of the baseline mean). In order to demonstrate a significant effect (p < 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies.</abstract><cop>Wien</cop><cop>New York, NY</cop><pub>Springer</pub><pmid>11716136</pmid><doi>10.1007/s007020170019</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-9564 |
| ispartof | Journal of Neural Transmission, 2001-01, Vol.108 (8-9), p.1011-1019 |
| issn | 0300-9564 1435-1463 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72287718 |
| source | MEDLINE; SpringerLink |
| subjects | Adult Aged Binding Sites - drug effects Binding Sites - physiology Binding, Competitive - drug effects Binding, Competitive - physiology Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disease Progression Dopamine - metabolism Female Humans Male Medical sciences Middle Aged Neostriatum - diagnostic imaging Neostriatum - pathology Neural Pathways - diagnostic imaging Neural Pathways - pathology Neurology Neuroprotective Agents - pharmacology Parkinson Disease - diagnostic imaging Parkinson Disease - pathology Presynaptic Terminals - diagnostic imaging Presynaptic Terminals - pathology Radionuclide Imaging Substantia Nigra - diagnostic imaging Substantia Nigra - pathology Tropanes - pharmacokinetics |
| title | [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T14%3A34%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5B123I%5DFP-CIT%20SPECT%20is%20a%20useful%20method%20to%20monitor%20the%20rate%20of%20dopaminergic%20degeneration%20in%20early-stage%20Parkinson's%20disease&rft.jtitle=Journal%20of%20Neural%20Transmission&rft.au=WINOGRODZKA,%20A&rft.date=2001-01-01&rft.volume=108&rft.issue=8-9&rft.spage=1011&rft.epage=1019&rft.pages=1011-1019&rft.issn=0300-9564&rft.eissn=1435-1463&rft.coden=JNTMAH&rft_id=info:doi/10.1007/s007020170019&rft_dat=%3Cproquest_cross%3E72287718%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18173686&rft_id=info:pmid/11716136&rfr_iscdi=true |